Omega Fund Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001637359

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 10 positions · Total reported value $185.69M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 27.3% · 1 new · 1 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +25.8% · vs SPY +11.0% · Prev Value $163.15M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Omega Fund Management, LLC disclosed 10 equity positions with a combined reported value of $185.69M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were BCAX ($54.10M), NUVB ($45.90M), KMTS ($26.00M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Omega Fund Management, LLC opened 1 new positions, trimmed 1 and fully exited 1, a turnover rate of 27.3% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q2 2026 were ODTX ($54.13K).

Of the 1 positions fully exited versus the prior quarter, the largest were REPL ($1.91M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ODTX ODYSSEY THERAPEUTICS INC · $54.13K

Fully Exited (vs previous quarter)

  • REPL REPLIMUNE GROUP INC · prev qtr: $1.91M

Insider Transactions (Form 4)

Latest Omega Fund Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Omega Fund Management, LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 10 positions worth $185.69M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-74224 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $1.71B as of 2026-03-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds
  • Website: omegafunds.com

Portfolio Structure

  • 10 positions · $185.69M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: BCAX (BICARA THERAPEUTICS INC) at 29.1%
  • Average position size: $18.57M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 reduced, 1 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Omega Fund Management's 2026-Q2 portfolio shows a conservative stance with a slight reduction in the position of BICARA Therapeutics Inc. This may suggest a cautious approach to market volatility or a preference for holding stable, well-established healthcare companies. 2. Key Moves: - Added: Odyssey Therapeutics Inc. (ODTX) was added to the portfolio as a new position, indicating a potential interest in emerging biotech or a specific drug development pipeline. - Reduced: BICARA Therapeutics Inc. (BCAX) saw a significant reduction of 23.8% in its share count, indicating a shift away from this particular investment. - Held: The fund maintained its positions in NUVATION BIO INC (NUVB), KESTRA MED TECHNOLOGIE F (KMTS), BridgeBio Oncology Therapeutic (BBOT), BETA BIONICS INC (BBNX), ALUMIS INC (ALMS), SANA BIOTECHNOLOGY INC (SANA), IMAGENEBIO INC (IMA), ENGENE THERAPEUTICS INC (ENGN), and Odyssey Therapeutics Inc. (ODTX), showing a preference for stability and a long-term view. 3. Portfolio Structure: - Passive vs. Active: The portfolio appears to be more passive in nature, with a focus on holding onto positions rather than frequent trading. - Sector Bias: The sector bias is clearly in healthcare, which constitutes the majority of the holdings. - Risk Appetite: The risk appetite is moderate, with a preference for stable companies and a reduction in one of the positions, suggesting a lower tolerance for volatility. 4. Per-Holding One-Liner: - BCAX: BICARA Therapeutics Inc. - Biotechnology company focused on novel therapies for cardiovascular diseases. (unverified) - NUVB: NUVATION BIO INC - Biotechnology company focusing on the development of therapies for cancer and rare diseases. - KMTS: KESTRA MED TECHNOLOGIE F - Medical technology company specializing in orthopedic and spine products. - BBOT: BridgeBio Oncology Therapeutic - Biotechnology company developing therapies for genetic disorders and rare cancers. - BBNX: BETA BIONICS INC - Medical device company specializing in advanced insulin pump technology. - ALMS: ALUMIS INC - Biotechnology company focused on the development of treatments for neurological disorders. - SANA: SANA BIOTECHNOLOGY INC - Biotechnology company focusing on the development of treatments for cancer and rare genetic disorders. - IMA: IMAGENEBIO INC - Biotechnology company working on therapies for various diseases, including cancer. - ENGN: ENGENE THERAPEUTICS INC - Biotechnology company focusing on the development of treatments for genetic disorders. - ODTX: Odyssey Therapeutics Inc. - Biotechnology company developing novel therapies for cancer and other diseases. (new addition) 5. One-Sentence Style Summary: Omega Fund Management maintained a cautious approach in Q2 2026, with a focus on healthcare sector stability and a strategic addition of a new biotech position.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.82M $54.10M 29.14%
29.14%
Reduce
2 8.08M $45.90M 24.72%
24.72%
Hold
3 1.02M $26.00M 14.00%
14.00%
Hold
4 3.29M $25.07M 13.50%
13.50%
Hold
5 1.32M $20.62M 11.11%
11.11%
Hold
6 241.25K $6.79M 3.66%
3.66%
Hold
7 843.75K $2.94M 1.59%
1.59%
Hold
8 455.36K $2.69M 1.45%
1.45%
Hold
9 876.36K $1.52M 0.82%
0.82%
Hold
10 2.89K $54.13K 0.03%
0.03%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 85% · recall 85% · F1 85% · avg rank error 1.8 · Top-10 turnover 16%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% LXEO · REPL · NUVB · ENGN · MORF · SPRB · KRON · IKNA · SANA · THRX NUVB · LXEO · REPL · ENGN · SANA · MORF · IKNA · IMUX · ENGNW · SYRS
2024-Q2 90% 90% 90% NUVB · LXEO · REPL · ENGN · SANA · MORF · IKNA · IMUX · ENGNW · SYRS NUVB · LXEO · REPL · ENGN · ALMS · MORF · SANA · IKNA · IMUX · SYRS
2024-Q3 80% 80% 80% NUVB · LXEO · REPL · ENGN · ALMS · MORF · SANA · IKNA · IMUX · SYRS BCAX · NUVB · REPL · LXEO · ENGN · ALMS · IKNA · SANA · IMUX · ENGNW
2024-Q4 90% 90% 90% BCAX · NUVB · REPL · LXEO · ENGN · ALMS · IKNA · SANA · IMUX · ENGNW BCAX · NUVB · UPB · REPL · LXEO · ALMS · IKNA · ENGN · IMUX · SANA
2025-Q1 80% 80% 80% BCAX · NUVB · UPB · REPL · LXEO · ALMS · IKNA · ENGN · IMUX · SANA KMTS · BCAX · BBNX · NUVB · REPL · UPB · LXEO · ALMS · IKNA · ENGN
2025-Q2 90% 90% 90% KMTS · BCAX · BBNX · NUVB · REPL · UPB · ALMS · LXEO · IKNA · ENGN BBNX · KMTS · UPB · NUVB · BCAX · REPL · LXEO · IKNA · SANA · ALMS
2025-Q3 70% 70% 70% BBNX · KMTS · UPB · NUVB · BCAX · REPL · LXEO · IKNA · SANA · ALMS KMTS · BBNX · BBOT · BCAX · NUVB · UPB · IMA · ENGN · SANA · ALMS
2025-Q4 100% 100% 100% KMTS · BBOT · BBNX · BCAX · NUVB · UPB · IMA · ENGN · SANA · ALMS NUVB · BBOT · BBNX · BCAX · KMTS · UPB · ENGN · ALMS · SANA · IMA
2026-Q1 90% 90% 90% NUVB · BBOT · BBNX · BCAX · KMTS · UPB · ENGN · ALMS · SANA · IMA BCAX · NUVB · BBOT · KMTS · BBNX · ENGN · ALMS · SANA · IMA · REPL
2026-Q2 ★ 90% 90% 90% BCAX · NUVB · BBOT · KMTS · BBNX · ENGN · ALMS · SANA · IMA · REPL BCAX · NUVB · KMTS · BBOT · BBNX · ALMS · SANA · IMA · ENGN · ODTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Omega Fund Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Omega Fund Management, LLC reported 10 equity positions worth $185.69M in aggregate; its largest disclosed positions were BCAX ($54.10M), NUVB ($45.90M), KMTS ($26.00M).

How large is Omega Fund Management, LLC's portfolio?

Omega Fund Management, LLC reported $185.69M of long equity holdings across 10 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Omega Fund Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/omega-fund-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →